Skip to main content
OpenTrials
Completed

NCT Number: NCT00430092

Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002b)

The purpose of this phase III study is to determine the efficacy of difluprednate in the treatment of inflammation following ocular surgery.

Completed

Looking for future studies?

Notify Me

Key information

Age range

2 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Comprehensive Eye Care

Washington, Missouri, 63090, United States

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Unilateral ocular surgery in the day prior to study enrollment.
  • Anterior chamber cell grade ≥ "2" on the day after surgery (Day 1).
  • Aged 2 years or older on the day of consent.
  • Negative urine pregnancy test on Day 1 for postmenarchal subjects; negative urine pregnancy test for premenarchal subjects at the investigator's discretion.
  • Provide signed written consent prior to entering the study or signed written consent from parent or legal guardian if subject is a minor and signed assent from minor subject, if appropriate.

Presurgical Exclusion Criteria:

  • Systemic administration of any corticosteroid in the 2 weeks prior to study enrollment.
  • Periocular injection in the study eye of any corticosteroid solution within 4 weeks prior to instillation of the study drug, or of any corticosteroid depot within 2 months prior to instillation of the study drug.
  • Instillation of any topical ocular corticosteroid or NSAID within 24 hours prior to instillation of the study drug or during the course of the study, with the exception of presurgical administration of a topical NSAID to prevent miosis.
  • Any history of glaucoma or ocular hypertension in the study eye.
  • History or presence of endogenous uveitis.
  • Any current corneal abrasion or ulceration.
  • Any confirmed or suspected active viral, bacterial, or fungal keratoconjunctival disease.
  • Allergy to similar drugs, such as other corticosteroids.
  • History of steroid-related IOP increase.
  • Scheduled surgery on the contralateral eye during the treatment period.
  • Unwilling to discontinue use of contact lenses during the study period.
  • Pregnancy or lactation.
  • Participation in any study of an investigational topical or systemic new drug or device within 30 days prior to screening, or at any time during the study.
  • Prior participation in the study described in this protocol.
  • Unable or unwilling to give signed informed consent prior to participation in any study related procedures.

Postsurgical Exclusion Criteria:

  • Ocular hemorrhage which interferes with evaluation of postsurgery inflammation.
  • Injection of gas into the vitreous body during surgery.
  • Presence of IOP ≥24 mm Hg on Day 1 after surgery.

Treatment and study plan

Difluprednate

Drug

Placebo

Drug

Primary outcomes

  1. Anterior Chamber Cell Grade of "0" on Day 8 (Difluprednate QID vs Placebo).

    Time frame: Day 8 (QID)

    Measured on a 0 to 4 scale: "0" is ≤ 1 cell; "1" is 2-10 cells; "2" is 11-20 cells; "3" is 21-50 cells; "4" is > 50 cells.

Sponsors and collaborators

Lead sponsor

Sirion Therapeutics, Inc.

Industry

Registry information

Official study title

A Phase 3 Multicenter, Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Difluprednate in the Treatment of Inflammation Following Ocular Surgery

Important dates

First posted
Feb 1, 2007
Registry last updated
Jul 2, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.